Clinical Trials Sponsored by Boehringer Ingelheim

Total 2562 results

Boehringer Ingelheim

Not yet recruiting

A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations

Healthy
Boehringer Ingelheim

Not yet recruiting

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Kidney Disease, Chronic
Boehringer Ingelheim

Recruiting

A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men

Healthy

Japan
Boehringer Ingelheim

Not yet recruiting

Real-life-persistence to Antifibrotic Treatments (REPEAT)

Idiopathic Pulmonary Fibrosis

France
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Diabetic Retinopathy

United States, Japan
Boehringer Ingelheim

Recruiting

JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

Kidney Disease, Chronic

Korea, Republic of
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

Depressive Disorder, Major

United States, China, Bulgaria, Czechia, Belgium, Japan, Germany
Boehringer Ingelheim

Recruiting

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Obesity | Overweight

China
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancer | Liver Cancer

Japan
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Glioma

Spain, United States, Germany, Netherlands, Austria, Switzerland
Boehringer Ingelheim

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma | Neuroendocrine Neoplasms

United States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, France, Portugal, Bulgaria
Boehringer Ingelheim

Recruiting

A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Liver Cirrhosis

Germany
Boehringer Ingelheim

Recruiting

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Liver Cirrhosis

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

Psoriasis

Bulgaria, Romania, Moldova, Republic of, Georgia
Boehringer Ingelheim

Recruiting

Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients

Lung Diseases, Interstitial

Greece
Boehringer Ingelheim

Recruiting

A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease

Lung Diseases, Interstitial

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Germany
Boehringer Ingelheim

Recruiting

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Heart Failure

Korea, Republic of
Boehringer Ingelheim

Recruiting

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

Obesity

Netherlands
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Neoplasm Metastasis | Non-Small Cell Lung Cancer

United States, Hong Kong, Korea, Republic of, China, Japan, Spain, Israel, Netherlands, Portugal, France, Sweden, Italy, Australia, United Kingdom, Belgium, Singapore, Germany, Austria
Boehringer Ingelheim

Terminated

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Crohn Disease

United States, Belgium, Germany, Hungary, Spain, United Kingdom, Czechia, Poland, Italy, Netherlands, Denmark
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Neoplasms | Non-squamous, Non-Small-Cell Lung Cancer

United States, Spain, Korea, Republic of, Taiwan, France, Hong Kong, United Kingdom, Germany, Australia, Poland, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body

Healthy

Germany
Boehringer Ingelheim

Active, not recruiting

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Obesity | Non-alcoholic Fatty Liver Disease

United States
Boehringer Ingelheim

Completed

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Finland, Spain, Denmark, Germany, Israel, Japan, Norway, Sweden, Taiwan, United Kingdom
Boehringer Ingelheim

Active, not recruiting

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Healthy

Belgium
Boehringer Ingelheim

Completed

Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

Healthy

Korea, Republic of
Boehringer Ingelheim

Suspended

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Solid Tumors

Spain, Canada, United States, Sweden
Boehringer Ingelheim

Completed

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Diabetic Nephropathies

Spain, Germany, United Kingdom, France, Greece, Portugal, Sweden, Russian Federation, Denmark, Slovakia
Boehringer Ingelheim

Completed

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Healthy

Germany
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight (SYNCHRONIZE™-2)

Obesity | Diabetes Mellitus, Type 2

Spain, United States, Korea, Republic of, Belgium, Australia, China, Poland, Japan, Canada, Finland, Germany, Greece, Hungary, New Zealand, Sweden, United Kingdom, Netherlands, Czechia, Denmark
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Solid Tumors, KRAS Mutation

Japan
Boehringer Ingelheim

Completed

ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years

Atrial Fibrillation

Taiwan
Boehringer Ingelheim

Active, not recruiting

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

Solid Tumors

Canada, United States, Japan
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

Chronic Kidney Disease

Spain, Canada, Australia, United States, Japan, Malaysia, United Kingdom, China, Mexico, Denmark, Russian Federation, Germany, Portugal, Hong Kong, Poland, Argentina, New Zealand, Sweden
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Kidney Disease, Chronic

United States, Spain, Korea, Republic of, Australia, Hong Kong, India, Canada, China, Germany, Italy, Japan, Malaysia, Belgium, Finland, Switzerland, Turkey, Hungary, Poland, Portugal, Philippines, Czechia, Greece, Bulgaria, Brazil, Arg... and more
Boehringer Ingelheim

Completed

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (PARTRIDGE)

Diabetic Retinopathy

Spain, United Kingdom, United States, Netherlands, Australia, Latvia
Boehringer Ingelheim

Completed

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare Two Different Sifrol® Tablets

Healthy

Germany
Boehringer Ingelheim

Active, not recruiting

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

Healthy

Germany
Boehringer Ingelheim

Completed

Influence of Fluvoxamine on the Pharmacokinetics of BI 409306

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Healthy

Germany
Boehringer Ingelheim

Completed

Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)

Pulmonary Disease, Chronic Obstructive | Pulmonary Emphysema

United States, Spain, Denmark, Belgium, Korea, Republic of, Canada, Germany, United Kingdom, Sweden, Finland, Japan, Poland

3

Subscribe